Skip to content

Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening

An Open-Label Treatment, Investigator-Initiated Study, on the Duration and Efficacy of Azstarys (Serdexmethylphenidate and Dexmethylphenidate) on Adult ADHD Symptoms and Executive Function in Early Evening

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06000501
Enrollment
29
Registered
2023-08-21
Start date
2023-11-13
Completion date
2024-07-17
Last updated
2025-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Attention Deficit Hyperactivity Disorder

Brief summary

This is a single-site study. One purpose of this trial is to extend the safety and efficacy evidence basis for Azstarys in adults with ADHD. This open-label, treatment study will examine the efficacy of Azstarys on ADHD symptoms using the AISRS 18-item total score on the AISRS-expanded; the Adult ADHD Investigator Symptom Rating Scale. The investigators will also examine Executive Function later in the day (early evening, about 12 hours after first morning dosing).

Interventions

DRUGSerdexmethylphenidate/dexmethylphenidate

Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.

Sponsors

Corium, Inc.
CollaboratorINDUSTRY
NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Adults ages 18-60 years, inclusive at the time of consent * Able to provide signed informed consent * Any gender * Subjects with a current primary DSM-5 diagnosis of ADHD of predominantly inattentive presentation, or combined presentations) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2.5, Subjects who are not receiving any pharmacological treatment for ADHD must have an AISRS 18 item total score of AISRS expanded of ≥ 28 at screening. Subjects who were previously receiving pharmacological treatment for ADHD at screening must have a minimum total AISRS 18 item of AISRS EXPANDED score of ≥ 22 at screening * Dysthymia and anxiety disorders in remission but stable on psychiatric medication for three weeks or more at the discretion of principal investigator will be allowed- medication for these disorders to remain constant for the duration of the protocol. * Subjects who are stimulant naïve.

Exclusion criteria

* Known hypersensitivity to serdexmethylphenidate, methylphenidate, or product components. * Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days. * Lifetime bipolar disorder, psychotic disorders, autism, intellectual disability except mood disorders accepted under the inclusion criteria at the discretion of the principal investigator. * Active suicidality within past year, or history of suicide attempt in past 2 years * Any history of severe past drug dependence determined by the MINI (i.e., a focus of clinical attention or a cause of substantial social or occupational difficulty) * Concurrent substance abuse and/or history of substance use within 6 months * Use of any prescribed benzodiazepine * Any unstable medical or neurological condition; clinically significant medical abnormalities such as cardiovascular abnormalities, and any chronic condition of the central nervous system. * Any psychotropic medication usage * Known nonresponse to MPH treatment * History of allergic reaction or sensitivity to MPH * Female of childbearing age, who are breastfeeding, pregnant, planning to be pregnant or men planning to make a woman pregnant during the study or for one-month post study * PI/clinician discretion

Design outcomes

Primary

MeasureTime frameDescription
Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Total ScoreWeek 2, Week 5The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 102; higher scores indicate more severe symptoms of ADHD.

Secondary

MeasureTime frameDescription
Change in Expanded AISRS - Hyperactive/Impulsive (HI) Subscale ScoreWeek 2, Week 5The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing hyperactive/impulsive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.
Change in Expanded AISRS - Overall Executive Dysfunction (EFD) Subscale ScoreWeek 2, Week 5The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing executive dysfunction symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.
Change in Expanded AISRS - Overall Emotional Control (EC) Subscale ScoreWeek 2, Week 5The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing emotional control symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.
Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist DSM-5 Expanded ScoreWeek 2, Week 5The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The total score is calculated as the sum of all item responses and ranges from 0 to 124, with higher scores indicating greater frequency of ADHD symptoms.
Change in 12-Hour Post-Dose TASS ScoreWeek 2, Week 518-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.
Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Inattentive (IA) Subscale ScoreWeek 2, Week 5The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The IA score ranges from 0-36. Higher scores indicating greater symptom severity.
Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Hyperactive (HI) Subscale ScoreWeek 2, Week 5The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The HI score ranges from 0-36. Higher scores indicating greater symptom severity.
Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Executive Dysfunction (EFD) Subscale ScoreWeek 2, Week 5The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The EFD score ranges from 0-36. Higher scores indicating greater symptom severity.symptoms.
Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Score Overall Emotional Dyscontrol (ED) Subscale ScoreWeek 2, Week 5The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The ED score ranges from 0-36. Higher scores indicating greater symptom severity.
Change in 1-Hour Post-Dose Time-Sensitive ADHD Symptom Scale (TASS) ScoreWeek 2, Week 518-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.
Change in Expanded AISRS - Overall Inattentive (IA) Subscale ScoreWeek 2, Week 5The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing inattentive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater overall inattentive symptoms.
Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose ScoreWeek 3AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.
Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose ScoreWeek 3AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.
Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose ScoreWeek 3AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.
Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose ScoreWeek 3AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.
Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose ScoreWeek 3AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.
AMSES - Overall Smoothness of Effect Scale ScoreWeek 3AMSES is is an assessment of the smoothness of effect of ADHD medication throughout the day following dosing. The overall smoothness of effect scale is a subscale part of the AMSES that asks participants to respond to How smooth do you think your medication effect is throughout the day? on a scale from 0 (never) to 100 (very often). The higher the score, the smoother the medication effect is throughout the day.
Change in Behavioral Regulation Index (BRI) T-ScoreWeek 2, Week 5The Behavioral Regulation Index (BRI) t-score on the BRIEF-A (Behavior Rating Inventory of Executive Function-Adult Version) is a summary measure of an individual's ability to regulate their behavior and emotions, 50 indicates the population mean with a standard deviation of 10. A t-score of 65 or higher indicates difficulties in behavioral regulation.
Change in Metacognition Index (MI) T-ScoreWeek 2, Week 5The Metacognition Index (MI) t-score on the BRIEF-A (Behavior Rating Inventory of Executive Function-Adult Version) is a measure of executive function that assesses an individual's ability to initiate, plan, organize, self-monitor, and manage their own cognitive processes, 50 indicates the population mean with a standard deviation of 10. A t-score of 65 or higher indicates difficulties with executive function related to planning, organization, and cognitive self-regulation.
Change in Global Executive Composite (GEC) T-scoreWeek 2, Week 5The Global Executive Composite (GEC) t-score on the BRIEF-A (Behavior Rating Inventory of Executive Function-Adult Version) is a summary measure of overall executive function, 50 indicates the population mean with a standard deviation of 10. A t-score of 65 or higher indicates difficulties with executive function in daily life.
Change in Clinical Global Impression-Severity (CGI-S) Scale ScoreWeek 2, Week 51-item clinician-rated assessment of the severity of a subject's mental illness. The severity of illness is rated as follows: 0 (not assessed), 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill subjects). The total score is the numerical ranking provided by the clinician.
Change in 4-Hour Post-Dose TASS ScoreWeek 2, Week 518-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

Countries

United States

Participant flow

Participants by arm

ArmCount
Adult ADHD Patients
Enrolled participants will begin with a two-week observation stabilization before starting treatment with Azstarys. Participants found to have ≥30% change in their total Adult ADHD Investigator Symptom Rating Scale (AISRS) scores during the two-week observation stabilization period treatment will be discontinued from the study. Remaining participants will be dispensed a three-week supply of Azstarys on a weekly basis. Serdexmethylphenidate/dexmethylphenidate: Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
17
Total17

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision4
Overall StudyPositive Urine Drug Test (UDT)1
Overall StudyScheduling issues2
Overall StudyScreen failure3
Overall StudySevere past drug dependence determined by the MINI2

Baseline characteristics

CharacteristicAdult ADHD Patients
Age, Continuous31.2 years
STANDARD_DEVIATION 8.9
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
8 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
8 Participants
Region of Enrollment
United States
17 participants
Sex: Female, Male
Female
10 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 29
other
Total, other adverse events
13 / 29
serious
Total, serious adverse events
0 / 29

Outcome results

Primary

Change in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score

The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 102; higher scores indicate more severe symptoms of ADHD.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Expanded Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score24.1 score on a scaleStandard Deviation 7.4
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 3

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose Score1.64 score on a scaleStandard Deviation 0.84
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose Score1.6 score on a scaleStandard Deviation 0.9
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 10-Hour Post Dose Score1.8 score on a scaleStandard Deviation 1.19
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 3

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose Score1.21 score on a scaleStandard Deviation 1.05
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose Score1.43 score on a scaleStandard Deviation 1.16
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 12-Hour Post Dose Score1.58 score on a scaleStandard Deviation 1.24
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 3

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose Score2.86 score on a scaleStandard Deviation 0.95
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose Score3.3 score on a scaleStandard Deviation 0.78
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 4-Hour Post Dose Score3 score on a scaleStandard Deviation 0.88
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose Score3.2 score on a scaleStandard Deviation 0.72
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose Score2.9 score on a scaleStandard Deviation 0.66
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 3

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 6-Hour Post Dose Score2.64 score on a scaleStandard Deviation 0.74
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose Score2.5 score on a scaleStandard Deviation 1
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 3

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose Score2.07 score on a scaleStandard Deviation 0.62
Secondary

Adult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose Score

AMSES is used to assess the smoothness of effect of ADHD medication at specified timepoints throughout the day (4, 6, 8, 10, and 12 hours after dosing). At each timepoint, participants are asked to rate whether the medication's effect feels the same as when they first took it in the morning, using a 5-point Likert scale ranging from 0 (never) to 4 (very often). Higher scores indicate greater smoothness of medication effect.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAdult ADHD Medication Smoothness of Effect Scale (AMSES) - 8-Hour Post Dose Score2.4 score on a scaleStandard Deviation 1.08
Secondary

AMSES - Overall Smoothness of Effect Scale Score

AMSES is is an assessment of the smoothness of effect of ADHD medication throughout the day following dosing. The overall smoothness of effect scale is a subscale part of the AMSES that asks participants to respond to How smooth do you think your medication effect is throughout the day? on a scale from 0 (never) to 100 (very often). The higher the score, the smoother the medication effect is throughout the day.

Time frame: Week 3

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAMSES - Overall Smoothness of Effect Scale Score69.64 score on a scaleStandard Deviation 14.47
Secondary

AMSES - Overall Smoothness of Effect Scale Score

AMSES is an assessment of the smoothness of effect of ADHD medication throughout the day following dosing. The overall smoothness of effect scale is a subscale part of the AMSES that asks participants to respond to How smooth do you think your medication effect is throughout the day? on a scale from 0 (never) to 100 (very often). The higher the score, the smoother the medication effect is throughout the day.

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAMSES - Overall Smoothness of Effect Scale Score75 score on a scaleStandard Deviation 21.92
Secondary

AMSES - Overall Smoothness of Effect Scale Score

AMSES is an assessment of the smoothness of effect of ADHD medication throughout the day following dosing. The overall smoothness of effect scale is a subscale part of the AMSES that asks participants to respond to How smooth do you think your medication effect is throughout the day? on a scale from 0 (never) to 100 (very often). The higher the score, the smoother the medication effect is throughout the day.

Time frame: Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsAMSES - Overall Smoothness of Effect Scale Score85.4 score on a scaleStandard Deviation 19.82
Secondary

Change in 12-Hour Post-Dose TASS Score

18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in 12-Hour Post-Dose TASS Score9.3 score on a scaleStandard Deviation 10.5
Secondary

Change in 1-Hour Post-Dose Time-Sensitive ADHD Symptom Scale (TASS) Score

18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in 1-Hour Post-Dose Time-Sensitive ADHD Symptom Scale (TASS) Score12.3 score on a scaleStandard Deviation 10
Secondary

Change in 4-Hour Post-Dose TASS Score

18-item assessment of ADHD symptoms. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (severe). The total score is the sum of responses and ranges from 0 to 54; higher scores indicate greater severity of symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in 4-Hour Post-Dose TASS Score12.6 score on a scaleStandard Deviation 10.5
Secondary

Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist DSM-5 Expanded Score

The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The total score is calculated as the sum of all item responses and ranges from 0 to 124, with higher scores indicating greater frequency of ADHD symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Adult ADHD Self Report Scale (ASRS) Symptom Checklist DSM-5 Expanded Score25.6 score on a scaleStandard Deviation 13.7
Secondary

Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Executive Dysfunction (EFD) Subscale Score

The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The EFD score ranges from 0-36. Higher scores indicating greater symptom severity.symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Executive Dysfunction (EFD) Subscale Score12.6 score on a scaleStandard Deviation 6.2
Secondary

Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Hyperactive (HI) Subscale Score

The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The HI score ranges from 0-36. Higher scores indicating greater symptom severity.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Hyperactive (HI) Subscale Score11.1 score on a scaleStandard Deviation 7.2
Secondary

Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Inattentive (IA) Subscale Score

The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The IA score ranges from 0-36. Higher scores indicating greater symptom severity.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Inattentive (IA) Subscale Score14.4 score on a scaleStandard Deviation 7.6
Secondary

Change in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Score Overall Emotional Dyscontrol (ED) Subscale Score

The ASRS is a 31-item questionnaire that assesses the frequency of ADHD symptoms over the past 7 days. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The ASRS includes several subscales: an Inattentive (IA) subscale (n = 9), a Hyperactive-Impulsive (HI) subscale (n = 9), an Executive Function Deficits (EFD) subscale (n = 9), and an Emotional Dyscontrol (ED) subscale (n = 4). It also yields a total combined ADHD symptom score. The ED score ranges from 0-36. Higher scores indicating greater symptom severity.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Adult ADHD Self Report Scale (ASRS) Symptom Checklist Score Overall Emotional Dyscontrol (ED) Subscale Score5.9 score on a scaleStandard Deviation 5
Secondary

Change in Behavioral Regulation Index (BRI) T-Score

The Behavioral Regulation Index (BRI) t-score on the BRIEF-A (Behavior Rating Inventory of Executive Function-Adult Version) is a summary measure of an individual's ability to regulate their behavior and emotions, 50 indicates the population mean with a standard deviation of 10. A t-score of 65 or higher indicates difficulties in behavioral regulation.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Behavioral Regulation Index (BRI) T-Score11.9 T-scoreStandard Deviation 12
Secondary

Change in Clinical Global Impression-Severity (CGI-S) Scale Score

1-item clinician-rated assessment of the severity of a subject's mental illness. The severity of illness is rated as follows: 0 (not assessed), 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill subjects). The total score is the numerical ranking provided by the clinician.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Clinical Global Impression-Severity (CGI-S) Scale Score1.7 score on a scaleStandard Deviation 1
Secondary

Change in Expanded AISRS - Hyperactive/Impulsive (HI) Subscale Score

The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing hyperactive/impulsive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Expanded AISRS - Hyperactive/Impulsive (HI) Subscale Score9.7 score on a scaleStandard Deviation 4.2
Secondary

Change in Expanded AISRS - Overall Emotional Control (EC) Subscale Score

The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing emotional control symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Expanded AISRS - Overall Emotional Control (EC) Subscale Score5.3 score on a scaleStandard Deviation 4.8
Secondary

Change in Expanded AISRS - Overall Executive Dysfunction (EFD) Subscale Score

The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing executive dysfunction symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater hyperactive/impulsive symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Expanded AISRS - Overall Executive Dysfunction (EFD) Subscale Score14.5 score on a scaleStandard Deviation 5.1
Secondary

Change in Expanded AISRS - Overall Inattentive (IA) Subscale Score

The expanded AISRS is an 34-item questionnaire assessing symptoms of adult ADHD. The 9-item subscale of the AISRS assessing inattentive symptoms of ADHD. Items are ranked on a 4-point Likert scale ranging from 0 (none) to 3 (severe). The total score is the sum of responses and ranges from 0 to 27; higher scores indicate greater overall inattentive symptoms.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Expanded AISRS - Overall Inattentive (IA) Subscale Score14.3 score on a scaleStandard Deviation 4
Secondary

Change in Global Executive Composite (GEC) T-score

The Global Executive Composite (GEC) t-score on the BRIEF-A (Behavior Rating Inventory of Executive Function-Adult Version) is a summary measure of overall executive function, 50 indicates the population mean with a standard deviation of 10. A t-score of 65 or higher indicates difficulties with executive function in daily life.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Global Executive Composite (GEC) T-score19.2 T-scoreStandard Deviation 14.3
Secondary

Change in Metacognition Index (MI) T-Score

The Metacognition Index (MI) t-score on the BRIEF-A (Behavior Rating Inventory of Executive Function-Adult Version) is a measure of executive function that assesses an individual's ability to initiate, plan, organize, self-monitor, and manage their own cognitive processes, 50 indicates the population mean with a standard deviation of 10. A t-score of 65 or higher indicates difficulties with executive function related to planning, organization, and cognitive self-regulation.

Time frame: Week 2, Week 5

ArmMeasureValue (MEAN)Dispersion
Adult ADHD PatientsChange in Metacognition Index (MI) T-Score22.1 T-scoreStandard Deviation 15.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026